Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07868010
ABSTRACT:
The invention relates to substituted pyrazinoylguanidine compounds. These compounds are useful as sodium channel blockers, and may be effective in treating a variety of conditions including chronic bronchitis and cystic fibrosis.
REFERENCES:
patent: 3313813 (1967-04-01), Cragoe, Jr. et al.
patent: 3527758 (1970-09-01), Cragoe, Jr. et al.
patent: 4246406 (1981-01-01), Cragoe, Jr. et al.
patent: 4894376 (1990-01-01), Morad et al.
patent: 6858614 (2005-02-01), Johnson
patent: 6858615 (2005-02-01), Johnson
patent: 6903105 (2005-06-01), Johnson
patent: 6995160 (2006-02-01), Johnson
patent: 7026325 (2006-04-01), Johnson
patent: 7030117 (2006-04-01), Johnson
patent: 7064129 (2006-06-01), Johnson et al.
patent: 7186833 (2007-03-01), Johnson
patent: 7189719 (2007-03-01), Johnson
patent: 7192958 (2007-03-01), Johnson
patent: 7192959 (2007-03-01), Johnson
patent: 7192960 (2007-03-01), Johnson
patent: 7241766 (2007-07-01), Johnson
patent: 7247636 (2007-07-01), Johnson
patent: 7247637 (2007-07-01), Johnson et al.
patent: 7317013 (2008-01-01), Johnson
patent: 7332496 (2008-02-01), Johnson
patent: 7345044 (2008-03-01), Johnson
patent: 7368447 (2008-05-01), Johnson et al.
patent: 7368450 (2008-05-01), Johnson
patent: 7368451 (2008-05-01), Johnson et al.
patent: 2005/0080092 (2005-04-01), Johnson
patent: 2005/0080093 (2005-04-01), Johnson et al.
patent: 2005/0090505 (2005-04-01), Johnson et al.
patent: 2005/0228182 (2005-10-01), Johnson et al.
patent: 2006/0040954 (2006-02-01), Johnson
patent: 2006/0142306 (2006-06-01), Johnson
patent: 2006/0142581 (2006-06-01), Johnson
patent: 2006/0205738 (2006-09-01), Johnson et al.
patent: 2007/0032509 (2007-02-01), Johnson et al.
patent: 2007/0265280 (2007-11-01), Johnson
patent: 2008/0076782 (2008-03-01), Johnson
patent: 2008/0090841 (2008-04-01), Johnson et al.
patent: 2008/0096896 (2008-04-01), Johnson
patent: 2008/0103148 (2008-05-01), Johnson
patent: 03/070182 (2003-08-01), None
patent: WO03070184 (2003-08-01), None
patent: 2004/073629 (2004-09-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
U.S. Appl. No. 60/495,725, filed Aug. 18, 2003, Johnson.
U.S. Appl. No. 60/495,720, filed Aug. 18, 2003, Johnson.
U.S. Appl. No. 60/495,712, filed Aug. 18, 2003, Johnson.
U.S. Appl. No. 60/602,312, filed Aug. 18, 2004, Johnson.
U.S. Appl. No. 60/602,327, filed Aug. 18, 2004, Johnson.
U.S. Appl. No. 60/812,091, filed Jun. 9, 2006, Johnson.
U.S. Appl. No. 60/812,077, filed Jun. 9, 2006, Johnson, et al.
U.S. Appl. No. 60/812,078, filed Jun. 9, 2006, Johnson.
U.S. Appl. No. 60/842,669, filed Sep. 7, 2006, Johnson, et al.
U.S. Appl. No. 60/842,963, filed Sep. 8, 2006, Johnson, et al.
U.S. Appl. No. 60/845,171, filed Sep. 18, 2006, Johnson, et al.
U.S. Appl. No. 60/909,818, filed Apr. 3, 2007, Johnson, et al.
U.S. Appl. No. 60/978,887, filed Oct. 10, 2007, Boucher, et al.
U.S. Appl. No. 60/978,874, filed Oct. 10, 2007, Boucher, et al.
U.S. Appl. No. 60/987,663, filed Nov. 13, 2007, Johnson, et al.
U.S. Appl. No. 61/013,387, filed Dec. 13, 2007, Johnson, et al.
U.S. Appl. No. 61/030,313, filed Feb. 21, 2008, Johnson.
U.S. Appl. No. 61/031,466, filed Feb. 26, 2008, Johnson.
U.S. Appl. No. 12/171,814, filed Jul. 11, 2008, Johnson. et al.
U.S. Appl. No. 12/171,867, filed Jul. 11, 2008, Johnson. et al.
U.S. Appl. No. 12/171,897, filed Jul. 11, 2008, Johnson. et al.
U.S. Appl. No. 12/190,022, filed Aug. 12, 2008, Johnson.
U.S. Appl. No. 61/079,989, filed Jul. 11, 2008, Boucher, et al.
U.S. Appl. No. 12/179,353, filed Jul. 24, 2008, Johnson.
U.S. Appl. No. 12/249,175, filed Oct. 10, 2008, Boucher, et al.
U.S. Appl. No. 12/304,006, filed Dec. 9, 2008, Johnson, et al.
U.S. Appl. No. 12/304,042, filed Dec. 9, 2008, Johnson.
U.S. Appl. No. 12/304,040, filed Dec. 9, 2008, Johnson.
U.S. Appl. No. 12/393,252, filed Feb. 26, 2009, Johnson.
U.S. Appl. No. 10/920,527, filed Aug. 18, 2004, Hopkins.
U.S. Appl. No. 11/573,413, filed Feb. 8, 2007, Johnson.
U.S. Appl. No. 11/573,421, filed Feb. 8, 2007, Johnson.
U.S. Appl. No. 11/696,003, filed Apr. 3, 2007, Johnson.
U.S. Appl. No. 11/852,003, filed Sep. 7, 2007, Johnson, et al.
U.S. Appl. No. 11/835,902, filed Aug. 8, 2007, Johnson, et al.
U.S. Appl. No. 12/049,946, filed Mar. 17, 2008, Johnson, et al.
U.S. Appl. No. 12/049,894, filed Mar. 17, 2008, Johnson, et al.
U.S. Appl. No. 12/050,010, filed Mar. 17, 2008, Johnson.
U.S. Appl. No. 12/049,993, filed Mar. 17, 2008, Johnson.
U.S. Appl. No. 12/050,019, filed Mar. 17, 2008, Johnson.
U.S. Appl. No. 12/061,837, filed Apr. 3, 2008, Johnson, et al.
U.S. Appl. No. 12/061,864, filed Apr. 3, 2008, Johnson, et al.
U.S. Appl. No. 12/098,581, filed Apr. 7, 2008, Johnson.
U.S. Appl. No. 12/501,654, filed Jul. 13, 2009, Boucher, et al.
E.J. Cragoe, Jr., et al., “Pyrazine Diuretics. II. N-Amidino-3-amino-5-substituted 6-Halopyrazinecarboxamides”, Journal of Medicinal Chemistry, vol. 10, No. 1, 1967, pp. 66-75.
T.R. Kleyman, et al., “Distinct Epitopes on Amiloride. II. Variably Restricted Epitopes Defined by Monoclonal Anti-antibodies”, American Journal of Physiology, vol. 260, No. 2, Part 1 of 2, 1991, pp. C271-C276.
T.M. Cocks, et al., “Amiloride Analogues Cause Endothelium-Dependent Relaxation in the Canine Coronary Artery in vitro: Possible Role of Na+/Ca+Exchange”, British Journal of Pharmacology, vol. 95, 1988, pp. 67-76.
Office Action issued Oct. 9, 2010, in Europe Patent Application No. 04781545.1.
Johnson Michael R.
Molino Bruce F.
Sargent Bruce
Zhang Jianzhong
Murray Jeffrey H
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Parion Sciences, Inc.
Wilson James O
LandOfFree
Capped pyrazinoylguanidine sodium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Capped pyrazinoylguanidine sodium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Capped pyrazinoylguanidine sodium channel blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2723914